Abstract
Purpose
To report a case of noninfectious endophthalmitis after intravitreal injection of aflibercept.
Case summary
A 67-year-old male patient presented with sudden vision loss 2 days after intravitreal aflibercept injection for neovascular age-related macular degeneration. Mild conjunctival injection and moderate inflammation in the anterior chamber were noted, but he had no ocular pain or hypopyon. The patient was diagnosed with noninfectious endophthalmitis and successfully treated with topical antibiotics and topical steroid eye drops. The infection was apparently cleared at 3 days. At 10 days after the initial presentation, his vision loss resolved completely.
References
1. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119:2537–48.
2. Goldberg RA, Shah CP, Wiegand TW, et al. Noninfectious abdominal after intravitreal injection of aflibercept: clinical abdominal and visual outcomes. Am J Ophthalmol. 2014; 158:733–7.e1.
3. Hahn P, Chung MM, Flynn HW Jr, et al. Postmarketing analysis of aflibercept-related sterile intraocular inflammation. JAMA abdominal. 2015; 133:421–6.
4. Hahn P, Kim JE, Stinnett S, et al. Aflibercept-related sterile inflammation. Ophthalmology. 2013; 120:1100–1.e1–5.
5. Fine HF, Roth DB, Shah SP, et al. Frequency and characteristics of intraocular inflammation after aflibercept injection. Retina. 2015; 35:681–6.
6. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation abdominal intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008; 246:779–81.
7. Kay CN, Tarantola RM, Gehrs KM, et al. Uveitis following abdominal bevacizumab: a noninfectious cluster. Ophthalmic Surg Lasers Imaging. 2011; 42:292–6.
8. Fauser S, Schroeder S, Caramoy A, et al. Intraocular inflammation after intravitreal ranibizumab injections. Acta Ophthalmol. 2011; 89:e98–9.
9. Sharma S, Johnson D, Abouammoh M, et al. Rate of serious abdominal effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012; 47:275–9.
10. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003; 87:972–4.
11. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003; 121:1279–82.
12. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and abdominal noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003; 23:686–91.
13. Damasceno N, Horowitz S, Damasceno E. Anterior uveitis after treatment ofage-related macular degeneration with ranibizumab and bevacizumab: uncommon complication. Clin Ophthalmol. 2012; 6:1201–5.
14. Cunningham MA, Tlucek P, Folk JC, et al. Sequential, acute noninfectious uveitis associated with separate intravitreal injections of bevacizumab and ranibizumab. Retin Cases Brief Rep. 2013; 7:355–8.
15. Celia F. Eylea's roaring rollout: though questions remain on long-term dosing, aflibercept has taken the retinal world by storm. Retinal Physician. 2012; 9:38–41.